Mehmet Onur Demirkol
Mehmet Onur Demirkol has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Burcu Uçar
Yildiz Teknik Üniversitesi
4 shared publications Hülya Seymen
Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Koc University, Istanbul, Turkey
4 shared publications- Dilek Yazici
Department of Endocrinology and Metabolism, Koc University Faculty of Medicine, Istanbul, Turkey
3 shared publications Fikret Turan
3 shared publicationsAlev Kadioğlu
2 shared publicationsBülent Mutlu
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Revisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Open AccessRevisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- 13 June 2023
- Published by SAGE Publications in The American Surgeon™
- Vol. 89 (12) , 5996-6004
Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
Aim: The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC). Methods: This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included. Results: The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease. Conclusion: This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value.
- 13 June 2023
- Published by SAGE Publications in The American Surgeon™
- Vol. 89 (12) , 5996-6004
Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
Aim: The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC). Methods: This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included. Results: The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease. Conclusion: This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value.
- 1 March 2020
- Published by Elsevier in European Urology Focus
- Vol. 6 (2) , 218-220
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
- 1 March 2020
- Published by Elsevier in European Urology Focus
- Vol. 6 (2) , 218-220
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
- 12 February 2020
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 277 (5) , 1491-1497
Effect of prophylactic central neck dissection on the surgical outcomes in papillary thyroid cancer: experience in a single center
Morbidity due to papillary thyroid carcinoma (PTC) is increased mostly due to lymph node (LN) metastases, which lead to reoperations and complications associated with these operations. The aim is to compare the outcomes of PTC having total thyroidectomy and prophylactic central lymph node dissection (TT + PCND) with patients having total thyroidectomy (TT) alone.
- 12 February 2020
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 277 (5) , 1491-1497
Effect of prophylactic central neck dissection on the surgical outcomes in papillary thyroid cancer: experience in a single center
Morbidity due to papillary thyroid carcinoma (PTC) is increased mostly due to lymph node (LN) metastases, which lead to reoperations and complications associated with these operations. The aim is to compare the outcomes of PTC having total thyroidectomy and prophylactic central lymph node dissection (TT + PCND) with patients having total thyroidectomy (TT) alone.
- 11 February 2020
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 45 (4) , 288-291
Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer
Purpose: 177Lu-PSMA inhibitor peptide receptor radioligand therapy (RLT) is playing an increasing role in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed radiation doses for critical organs (eg, kidneys, parotid glands, submandibular glands, and lacrimal glands) of patients treated with 4 to 6 cycles by 177Lu-PSMA inhibitor RLT, retrospectively, and to evaluate the findings extensively in order to determine the critical organ radiation-absorbed limitations and the number of prospective RLT. Materials and Methods: A total of 51 cycles 177Lu-PSMA inhibitor RLT in 10 patients was analyzed. Therapies have been applied in 4 to 6 cycles with 8 to 10 weeks' intervals. Dosimetric estimates of kidneys, parotid glands, submandibular glands, and lacrimal glands have been calculated based on MIRD scheme pamphlet no. 16. Regions of interest were drawn with GE Xeleris Functional Imaging Workstation. OLINDA/EXM 1.1 simulation software was used to calculate radiation-absorbed doses. Results: Mean radiation-absorbed doses were 0.70 ± 0.24 Gy/GBq for kidneys, 1.34 ± 0.78 Gy/GBq for parotid glands, 0.94 ± 0.45 Gy/GBq for submandibular glands, and 2.28 ± 1.29 Gy/GBq for lacrimal glands. Conclusions: Due to the critical target organ risks and the optimal therapy doses, patient-specific dosimetry is a deterministic factor in radionuclide therapy. Even when the absorbed kidney doses were above the ICRP critical dose limits in patients who had 4 to 6 cycles of therapy, mortality due to nephrotoxicity has not been observed. Mild increased tolerated radiation dose is acceptable for the patient groups with very low survival rate.
- 11 February 2020
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 45 (4) , 288-291
Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer
Purpose: 177Lu-PSMA inhibitor peptide receptor radioligand therapy (RLT) is playing an increasing role in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed radiation doses for critical organs (eg, kidneys, parotid glands, submandibular glands, and lacrimal glands) of patients treated with 4 to 6 cycles by 177Lu-PSMA inhibitor RLT, retrospectively, and to evaluate the findings extensively in order to determine the critical organ radiation-absorbed limitations and the number of prospective RLT. Materials and Methods: A total of 51 cycles 177Lu-PSMA inhibitor RLT in 10 patients was analyzed. Therapies have been applied in 4 to 6 cycles with 8 to 10 weeks' intervals. Dosimetric estimates of kidneys, parotid glands, submandibular glands, and lacrimal glands have been calculated based on MIRD scheme pamphlet no. 16. Regions of interest were drawn with GE Xeleris Functional Imaging Workstation. OLINDA/EXM 1.1 simulation software was used to calculate radiation-absorbed doses. Results: Mean radiation-absorbed doses were 0.70 ± 0.24 Gy/GBq for kidneys, 1.34 ± 0.78 Gy/GBq for parotid glands, 0.94 ± 0.45 Gy/GBq for submandibular glands, and 2.28 ± 1.29 Gy/GBq for lacrimal glands. Conclusions: Due to the critical target organ risks and the optimal therapy doses, patient-specific dosimetry is a deterministic factor in radionuclide therapy. Even when the absorbed kidney doses were above the ICRP critical dose limits in patients who had 4 to 6 cycles of therapy, mortality due to nephrotoxicity has not been observed. Mild increased tolerated radiation dose is acceptable for the patient groups with very low survival rate.
- Open Access
- 1 January 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (2) , 360-368
The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients
Background/aim: The aim of this study is to investigate clinicopathologic features of familial papillary thyroid carcinoma (fPTC) and compare them with sporadic papillary thyroid carcinoma (sPTC) in Turkish patients. A retrospective analysis of the papillary thyroid carcinoma (PTC) cases, with or without family history with a follow-up around 10 years was performed. Materials and methods: A series of patients with fPTC (82 fPTC families with 116 affected individuals) were compared with patients with sPTC (n = 112). The clinicopathologic features [(age, gender, histologic subtype, tumour size, bilaterally, multifocality, extrathyroidal extension (FEE), lymph node metastasis (LNM)I and treatment procedures (lymph node dissection, radioactive iodine ablation), and the outcomes like recurrences in the neck region, distant metastasis, and the need for reoperation were compared between the groups. Results: Vhen the groups were compared, there was no significant difference in age (P = 0.449), and tumour size (P 0.898) between familial and sporadic PTC patients. 0,TC group had a significantly higher risk of male gender (P = 0.001), bilaterally (P =0.004), multilocality (P 0.011), LNM (P = 0.013), PTE (P = 0.040), and distant metastasis (P < 0.0001) than the sPTC group. However, recurrence rate was similar between the 2 groups (13 = 0A36). Conclusion: The results of this study confirms a inure aggressive nature in fPTC patients, in terms of bilaterally, nuiltifocality, ETE, LNM, and distant metastasis, compared to sPTC patients in Turkish population.
- 1 January 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (2) , 360-368
Open AccessThe clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients
Background/aim: The aim of this study is to investigate clinicopathologic features of familial papillary thyroid carcinoma (fPTC) and compare them with sporadic papillary thyroid carcinoma (sPTC) in Turkish patients. A retrospective analysis of the papillary thyroid carcinoma (PTC) cases, with or without family history with a follow-up around 10 years was performed. Materials and methods: A series of patients with fPTC (82 fPTC families with 116 affected individuals) were compared with patients with sPTC (n = 112). The clinicopathologic features [(age, gender, histologic subtype, tumour size, bilaterally, multifocality, extrathyroidal extension (FEE), lymph node metastasis (LNM)I and treatment procedures (lymph node dissection, radioactive iodine ablation), and the outcomes like recurrences in the neck region, distant metastasis, and the need for reoperation were compared between the groups. Results: Vhen the groups were compared, there was no significant difference in age (P = 0.449), and tumour size (P 0.898) between familial and sporadic PTC patients. 0,TC group had a significantly higher risk of male gender (P = 0.001), bilaterally (P =0.004), multilocality (P 0.011), LNM (P = 0.013), PTE (P = 0.040), and distant metastasis (P < 0.0001) than the sPTC group. However, recurrence rate was similar between the 2 groups (13 = 0A36). Conclusion: The results of this study confirms a inure aggressive nature in fPTC patients, in terms of bilaterally, nuiltifocality, ETE, LNM, and distant metastasis, compared to sPTC patients in Turkish population.
- 1 April 2018
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (2) , 99-102
Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177
- 1 April 2018
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (2) , 99-102
Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177
- 1 May 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (5) , 403-405
The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. 68Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla. This finding confirmed metastatic poorly differentiated prostate cancer, and androgen deprivation therapy was initiated.
- 1 May 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (5) , 403-405
The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. 68Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla. This finding confirmed metastatic poorly differentiated prostate cancer, and androgen deprivation therapy was initiated.
- 18 January 2015
- Published by Wiley in The Prostate
- Vol. 75 (7) , 748-757
Prostate‐specific membrane antigen‐based imaging in prostate cancer: Impact on clinical decision making process
BACKGROUND: There is an ongoing need for an accurate imaging modality which can be used for staging purposes, metastatic evaluation, predicting biologic aggresiveness and investigating recurrent disease in prostate cancer. Prostate specific membrane antigen, given its favorable molecular characteristics, holds a promise as an ideal target for prostate cancer‐specific nuclear imaging. In this study, we evaluated our initial results of PSMA based PET/CT imaging in prostate cancer.METHODS: A total of 22 patients with a median age and serum PSA level of 68 years and 4.15 ng/ml, respectively underwent Ga‐68 PSMA PET/CT in our hospital between Februrary and August 2014. Their charts were retrospectively reviewed in order to document the clinical characteristics, the indications for and the results of PSMA based imaging and the impact of Ga‐68 PSMA PET/CT findings on disease management.RESULTS: The most common indications were rising PSA after local ± adjuvant treatment followed by staging and metastatic evaluation before definitive or salvage treatment. All except 2 patients had prostatic ± extraprostatic PSMA positive lesions. For those who had a positive result; treatment strategies were tailored accordingly. Above the PSA level of 2 ng/ml, none of the PSMA based nuclear imaging studies revealed negative results.CONCLUSIONS: PSMA based nuclear imaging has significantly impacted our way of handling patients with prostate cancer. Its preliminary performance in different clinical scenarios and ability to detect lesions even in low PSA values seems fairly promising and deserves to be supplemented with further clinical studies. Prostate 75:748–757, 2015.
- 18 January 2015
- Published by Wiley in The Prostate
- Vol. 75 (7) , 748-757
Prostate‐specific membrane antigen‐based imaging in prostate cancer: Impact on clinical decision making process
BACKGROUND: There is an ongoing need for an accurate imaging modality which can be used for staging purposes, metastatic evaluation, predicting biologic aggresiveness and investigating recurrent disease in prostate cancer. Prostate specific membrane antigen, given its favorable molecular characteristics, holds a promise as an ideal target for prostate cancer‐specific nuclear imaging. In this study, we evaluated our initial results of PSMA based PET/CT imaging in prostate cancer.METHODS: A total of 22 patients with a median age and serum PSA level of 68 years and 4.15 ng/ml, respectively underwent Ga‐68 PSMA PET/CT in our hospital between Februrary and August 2014. Their charts were retrospectively reviewed in order to document the clinical characteristics, the indications for and the results of PSMA based imaging and the impact of Ga‐68 PSMA PET/CT findings on disease management.RESULTS: The most common indications were rising PSA after local ± adjuvant treatment followed by staging and metastatic evaluation before definitive or salvage treatment. All except 2 patients had prostatic ± extraprostatic PSMA positive lesions. For those who had a positive result; treatment strategies were tailored accordingly. Above the PSA level of 2 ng/ml, none of the PSMA based nuclear imaging studies revealed negative results.CONCLUSIONS: PSMA based nuclear imaging has significantly impacted our way of handling patients with prostate cancer. Its preliminary performance in different clinical scenarios and ability to detect lesions even in low PSA values seems fairly promising and deserves to be supplemented with further clinical studies. Prostate 75:748–757, 2015.